0 CHECKOUT

PRODUCT FILTERS

REGION

CATEGORIES

  • 8
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1

PRICE

12
13
14
21

PUBLISHED

0
4
5
21

PRODUCT TYPE

10
7
3
1

Search for: "Schering-Plough: Pipeline - Products - Performance - Potential"

21 Products

Big Pharma's Key Lifecycle Management Strategies - Maximizing the Market Potential

“Big Pharma's Key Lifecycle Management Strategies: Maximizing the Market Potential ” provides key data, information and analysis on the key lifecycle management strategies implemented by pharmaceutical...

Published:  February 2010
Price:  From

Global Biosimilars Market, 2015 - 2025

Characterised by increased utility in chronic diseases and capital intensive manufacturing, the global biopharmaceutical market is expanding robustly. As the demand for biologics is increasing continuously,...

Published:  July 2015
Price:  From

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022

Tildrakizumab (Psoriasis) - Forecast and Market Analysis to 2022 Summary Psoriasis is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2–3% worldwide...

Published:  May 2013
Price:  From

The Global Cancer Vaccine Market, 2nd Edition: Pipeline Analysis and Future Market Impact

In 2010, the therapeutic cancer vaccine market witnessed several key milestones Dendreon's Provenge (sipuleucel-T) became the first product to reach the market; gaining long-awaited FDA approval for...

Published:  January 2011
Price:  From

Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025

Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to...

Published:  July 2015
Price:  From

The Medicines Company (MDCO) - Financial and Strategic SWOT Analysis Review

The Medicines Company (MDCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled...

Published:  June 2015
Price:  From

Vivus, Inc. (VVUS) - Financial and Strategic SWOT Analysis Review

Vivus, Inc. (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by The publisher...

Published:  May 2015
Price:  From

Agenix Limited (AGX) - Financial and Strategic SWOT Analysis Review

Agenix Limited (AGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData...

Published:  January 2014
Price:  From

Small Molecule Kinase Inhibitors - Global Strategic Business Report

This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb,...

Published:  July 2009
Price:  From

Prefilled Syringes Market (3rd Edition), 2015 - 2025

Injectable drug delivery systems have traversed a long way from conventional syringes with vials to prefilled syringes, auto-injectors, pen injectors and needle free systems. These modern devices have...

Published:  June 2015
Price:  From

The Rheumatoid Arthritis Market: Competitive Landscape and Clinical Stage Analysis

Rheumatoid arthritis, a systemic disease characterized by inflammation of the membrane lining the joint, is one of the most common forms of arthritis Up to 50 percent of all rheumatoid arthritis patients...

Published:  May 2009
Price:  From

Dyslipidemia: Opportunities in Cardiovascular Risk Reduction

This report examines trends in the dyslipidemia market, which is poised for transformation with the advent of novel combination products and biopharmaceuticals Cholesterol (LDL and HDL) and triglycerides...

Published:  July 2008
Price: 

Colorectal Cancer (CRC) Therapeutics - Global Strategic Business Report

This report analyzes the worldwide markets for Colorectal Cancer Therapeutics in US$ Million The major product segments analyzed are Cytotoxic Therapies (5-FU (Fluorouracil), Camptosar (Irinotecan),...

Published:  October 2006
Price:  From

Inhibitex, Inc. (INHX) - Financial and Strategic Analysis Review

Inhibitex, Inc. (Inhibitex) is a development stage biopharmaceutical company engaged in the research and development of innovative products for the treatment of serious infectious diseases. The pipeline...

Published:  July 2010
Price:  From

Credit Trends: Downgrade Potential Across Credit Grades And Sectors Feb 06

Abstract A total of 636 entities appeared at risk globally of potential downgrades as of Feb. 22, 2006, compared with 620 in mid-January. Almost 87% of those at risk of downgrades were located either...

Published:  February 2006
Price: 

Credit Trends: Downgrade Potential Across Credit Grades And Sectors Nov 05

Abstract A total of 656 entities appeared at risk globally of potential downgrades as of Nov. 21, 2005, compared with 649 in mid-September. 87% of those at risk of downgrades were located either in...

Published:  November 2005
Price: 

Credit Trends: Downgrade Potential Across Credit Grades And Sectors Dec 05

Abstract A total of 632 entities appeared at risk globally of potential downgrades as of Dec. 21, 2005, compared with 656 in mid-November. 87% of those at risk of downgrades were located either in...

Published:  December 2005
Price: 

Credit Trends: Downgrade Potential Across Credit Grades And Sectors Oct 05

Abstract A total of 649 entities appeared at risk globally of potential downgrades as of Oct. 26, 2005, compared with 632 in mid-September. 88% of those at risk of downgrades were located either in...

Published:  October 2005
Price: 

Credit Trends: Downgrade Potential Across Credit Grades And Sectors Sep 05

Abstract A total of 632 entities appeared at risk globally of potential downgrades in mid-September 2005. This is the first publication in a series of reports that will monitor issuers at risk of downgrades...

Published:  September 2005
Price: 

Credit Trends: Downgrade Potential Across Credit Grades And Sectors Mar 06

Abstract This month, we note the following key takeaways: The number of entities at risk of potential downgrades jumped to a high of 659 in mid-March, compared with 636 in mid-February. This count...

Published:  March 2006
Price: 
Loading Indicator

Our Clients

  • Innocent Drinks Ltd.
  • Groupe Danone
  • Cisco Systems, Inc.
  • The World Bank Group
  • Swarovski AG
  • Owens Corning Corporation
  • Swiss Reinsurance Company Ltd.